• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

michelle.yong@unimelb.edu.au

Credentials


Position
Honorary Conjoint Principal Fellow
The Sir Peter MacCallum Department of Oncology
ORCID

0000-0002-8692-4145

A/Prof Michelle Yong

Honorary Conjoint Principal Fellow
The Sir Peter MacCallum Department of Oncology

78 Scholarly works
5 Projects

HIGHLIGHTS

  • 2026

    Journal article

    Human Cytomegalovirus Infection in Haematopoietic Stem Cell Transplant Recipients and CAR T Cell Recipients – PART 1: Risk Factors, Clinical Impact and Immune Response
    DOI: 10.1002/rmv.70142
  • 2026

    Journal article

    Human Cytomegalovirus Infection in Haematopoietic Stem Cell Transplant Recipients and CAR-T Cell Recipients—PART 2: Antiviral Therapy and Virus-Specific T Cell Therapy for HCMV in Allo-HSCT
    DOI: 10.1002/rmv.70135
  • 2026

    Journal article

    Antiviral prophylaxis against herpesviruses (herpes simplex virus, varicella-zoster virus and cytomegalovirus) among patients with cancer.
    DOI: 10.1097/QCO.0000000000001198
  • 2026

    Journal article

    Cytomegalovirus reactivation in multiple myeloma patients receiving bispecific antibodies.
    DOI: 10.1182/bloodadvances.2025019563
  • 2024

    Research grants (ARC, NHMRC, MRFF)

    Transforming Infection Management in the Era of Emerging Cancer Therapies
  • 2022

    Research grants (ARC, NHMRC, MRFF)

    Improving Patient Outcomes Through Implementation of Digital and Diagnostic Innovations for Infections in Cancer
  • 2020

    Research Grant

    ProTreat: An Adaptive and Rapid Implementation Trial of Novel Therapies to Prevent and Treat COVID19 Infection in High Risk Cancer Patients
Michelle Yong

RECENT SCHOLARLY WORKS

  • 2026

    Journal article

    QuantiFERON-CMV Monitoring Post-Allogeneic Hematopoietic Stem Cell Transplantation Is Dynamic and Predictive of Immediate Cytomegalovirus Outcomes
    DOI: 10.1111/tid.70152
  • 2026

    Journal article

    Rhino-sino-orbital and/or central nervous system infections due to Lomentospora prolificans and Scedosporium spp. in onco-haematology patients
    DOI: 10.1093/mmy/myag016
  • 2026

    Journal article

    Interferon-α Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial
    DOI: 10.1093/cid/ciaf409
  • 2026

    Journal article

    Infection Prevention and Surveillance in the Care of Australasian Solid-Organ Transplant Recipients
    DOI: 10.1111/tid.70149
  • 2025

    Journal article

    Influenza-Specific T-Cell Responses to Vaccination Are Independent of Underlying Hematological Malignancy: Analysis of a Randomized Influenza Vaccination Trial
    DOI: 10.1093/infdis/jiaf297
  • 2025

    Journal article

    Antifungal prophylaxis in patients with FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD)-positive acute myeloid leukaemia receiving sorafenib during initial induction and consolidation treatment in ALLG AMLM16 trial
    DOI: 10.1093/jac/dkaf385

RECENT PROJECTS

  • 2024

    Research grants (ARC, NHMRC, MRFF)

    ADAPT (Achieving Durable Remission via Adaptive Pro-Survival Targeting in Acute Myeloid Leukaemia)
  • 2026

    Research grants (international)

    Isavuconazole Treatment and Prophylaxis in Adult and Paediatric Patients With Cancer - A Multicentre National Study (The SHIELD Study)

We acknowledge and pay respect to the Traditional Owners of the lands upon which our campuses are situated

Read about our commitment to reconciliation  

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia


View all Campus locations  
facebookIconlinkedinIconinstagramIcontwitterIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy  |  VaxFACTS

CRICOS number: 00116K     ABN: 84 002 705 224